Current Hematologic Malignancy Reports

, Volume 4, Issue 3, pp 148–156 | Cite as

Novel therapies for relapsed acute lymphoblastic leukemia

  • Amber Fullmer
  • Susan O’Brien
  • Hagop Kantarjian
  • Elias Jabbour


The outcome of salvage therapy for relapsed acute lymphoblastic leukemia (ALL) remains poor. Salvage therapy mimics regimens with activity in newly diagnosed ALL. Novel strategies under investigation as monotherapy or in combination with chemotherapy improve the treatment of relapsed disease. For some ALL subsets, specific therapies are indicated. The addition of targeted therapy in Philadelphia chromo some-positive ALL has improved responses in relapsed patients without resistance to available tyrosine kinase inhibitors. Nelarabine demonstrates activity as monotherapy in T-cell ALL and is approved by the US Food and Drug Administration. Clofarabine, a second-generation purine analogue approved in pediatric leukemia, has shown activity in adult acute leukemias including ALL and acute myeloid leukemia. The role of pegaspargase in adult ALL requires further investigation. The benefit of matched related-donor allogeneic stem cell transplantation is significant for standard-risk ALL but not for high-risk ALL. Development of new drugs and agents tailored to subset-specific cytogenetic-molecular characteristics remains vital to success in treating adult ALL.


Imatinib Acute Lymphoblastic Leukemia Dasatinib Autologous Stem Cell Transplantation Asparaginase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Jemal A, Tiwari RC, Murray T, et al.: Cancer statistics, 2004. CA Cancer J Clin 2004, 54:8–29.PubMedCrossRefGoogle Scholar
  2. 2.
    Jabbour EJ, Faderl S, Kantarjian HM: Adult acute lymphoblastic leukemia. Mayo Clin Proc 2005, 80:1517–1527.PubMedCrossRefGoogle Scholar
  3. 3.
    Bennett JM, Catovsky D, Daniel MT, et al.: Proposals for the classification of acute leukemia. French-American-British Cooperative Group. Br J Haematol 1976, 33:451–458.PubMedCrossRefGoogle Scholar
  4. 4.
    Harris NL, Jaffe ES, Diebold J, et al.: World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997. J Clin Oncol 1999, 17:3835–3849.PubMedGoogle Scholar
  5. 5.
    World Health Organization. In World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Edited by Jaffe ES, Harris NL, Stein H, Vardiman JW. Lyon, France: IARC Press; 2001:111–187.Google Scholar
  6. 6.
    Thomas DA, Kantarjian H, Smith TL, et al.: Primary refractory and relapsed adult acute lymphoblastic leukemia. Cancer 1999, 86:1216–1230.PubMedCrossRefGoogle Scholar
  7. 7.
    O’Brien S, Thomas D, Ravandi F, et al.: Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 2008, 113:3186–3191.PubMedCrossRefGoogle Scholar
  8. 8.
    Kantarjian HM, O’Brien S, Smith T, et al.: Acute lymphocytic leukaemia in the elderly: characteristics and outcome with the vincristine-Adriamycin-dexamethasone (VAD) regimen. Br J Haematol 1994, 88:94–100.PubMedCrossRefGoogle Scholar
  9. 9.
    Jones B, Freeman AI, Shuster JJ, et al.: Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol 1991, 19:269–275.PubMedCrossRefGoogle Scholar
  10. 10.
    Hurwitz CA, Silverman LB, Schorin MA, et al.: Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer 2000, 88:1964–1969.PubMedCrossRefGoogle Scholar
  11. 11.
    Ottman OG, Hoelzer D, Gracien E, et al.: Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial. Blood 1995, 86:444–450.Google Scholar
  12. 12.
    Kantarjian HM, O’Brien S, Smith TL, et al.: Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000, 18:547–561.PubMedGoogle Scholar
  13. 13.
    Cortes J, O’Brien SM, Pierce S, et al.: The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood 1995, 86:2091–2097.PubMedGoogle Scholar
  14. 14.
    Mahmoud DH Jr, Rivera GK, Hancock ML, et al.: Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. N Engl J Med 1993, 329:314–319.PubMedCrossRefGoogle Scholar
  15. 15.
    Laack NN, Brown PD: Cognitive sequelae of brain radiation in adults. Semin Oncol 2004, 31:702–713.PubMedCrossRefGoogle Scholar
  16. 16.
    Pui C-H, Cheng C, Leung W, et al.: Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med 2003, 349:640–649.PubMedCrossRefGoogle Scholar
  17. 17.
    Tucker J, Prior PF, Green CR, et al.: Minimal neuropsychological sequelae following prophylactic treatment of the central nervous system in adult leukemia and lymphoma. Br J Cancer 1989, 60:775.PubMedGoogle Scholar
  18. 18.
    Pui CH: Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment. Hematology Am Soc Hematol Educ Program 2006:142–146.Google Scholar
  19. 19.
    Rudnick SA, Cadman EC, Capizzi RL, et al.: High dose cytosine arabinoside (HDARAC) in refractory acute leukemia. Cancer 1979, 44:1189–1193.PubMedCrossRefGoogle Scholar
  20. 20.
    Capizzi RL, Yang JL, Cheng E, et al.: Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia. J Clin Oncol 1983, 1:763–771.PubMedGoogle Scholar
  21. 21.
    Hande KR, Stein RS, McDonough DA, et al.: Effects of high-dose cytarabine. Clin Pharmacol Ther 1982, 31:669–674.PubMedGoogle Scholar
  22. 22.
    Ackland SP, Schilsky RL: High-dose methotrexate: a critical reappraisal. J Clin Oncol 1987, 5:2017–2031.PubMedGoogle Scholar
  23. 23.
    Wellwood J, Taylor K: Central nervous system prophylaxis in hematological malignancies. Int Med J 2002, 32:252–258.CrossRefGoogle Scholar
  24. 24.
    Gökbuget N, Hoelzer D: High-dose methotrexate in the treatment of adult lymphoblastic leukemia. Ann Hematol 1996, 72:194–201.PubMedCrossRefGoogle Scholar
  25. 25.
    Kantarjian HM, Walters RS, Smith TL, et al.: Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia. Blood 1988, 72:1784–1789.PubMedGoogle Scholar
  26. 26.
    Kantarjian H, Thomas D, O’Brien S, et al.: Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004, 101:2788–2801.PubMedCrossRefGoogle Scholar
  27. 27.
    Foroni L, Coyle LA, Papaioannou M, et al.: Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment and response. Leukemia 1997, 11:1732–1741.PubMedCrossRefGoogle Scholar
  28. 28.
    Thomas DA, Faderl S, Cortes J, et al.: Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004, 103:4396–4407.PubMedCrossRefGoogle Scholar
  29. 29.
    Thomas DA, Faderl S, Cortes J, et al.: Update of the hyper-CVAD and imatinib mesylate regimen in Philadelphia (Ph) positive acute lymphocytic leukemia (ALL) [abstract 2738]. Blood (ASH Annual Meeting Abstracts) 2004, 104:748a.Google Scholar
  30. 30.
    Ravandi F, Thomas D, Kantarjian H, et al.: Phase II study of combination of hyperCVAD with dasatinib in frontline therapy of patients with Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL) [abstract 2921]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 2921.Google Scholar
  31. 31.
    Thomas DA, Cortes J, Faderl S, et al.: Hyper-CVAD and rituximab therapy in HIV-negative Burkitt (BL) or Burkittlike (BLL) leukemia/lymphoma and mature B-cell acute lymphocytic leukemia (B-ALL) [abstract]. ASCO Annual Meeting Proc 2005, 23:567s.Google Scholar
  32. 32.
    Thomas DA, Cortes J, O’Brien S, et al.: Hyper-CVAD program in Burkitt’s-type adult acute lymphoblastic leukemia. J Clin Oncol 1999, 17:2461–2470.PubMedGoogle Scholar
  33. 33.
    DeAngelo DJ, Yu D, Johnson JL, et al.: Nelarabine induces complete remission in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood 2007, 109:5136–5142.PubMedCrossRefGoogle Scholar
  34. 34.
    O’Brien S, Thomas DA, Ravandi F, et al.: Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer 2008, 113:2097–2101.PubMedCrossRefGoogle Scholar
  35. 35.
    Jeha S, Razzouk BI, Rytting ME, et al.: Phase II trials of clofarabine in relapsed or refractory pediatric leukemia [abstract 684]. Blood 2004, 104:196a.Google Scholar
  36. 36.
    Kantarjian HM, Gandhi V, Kozuch P, et al.: Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003, 21:1167–1173.PubMedCrossRefGoogle Scholar
  37. 37.
    Kantarjian H, Gandhi V, Cortes J, et al.: Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003, 102:2379–2386.PubMedCrossRefGoogle Scholar
  38. 38.
    Jeha S, Kantarjian H: Clofarabine for the treatment of acute lymphoblastic leukemia. Expert Rev Anticancer Ther 2007, 7:113–118.PubMedCrossRefGoogle Scholar
  39. 39.
    Faderl S, Thomas DA, Koller CA, et al.: Hyper-CVAD plus nelarabine: a pilot study for patients with newly diagnosed T cell acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LL) [abstract 3960]. Blood 2008, 112:Abstract 3960.Google Scholar
  40. 40.
    Thomas DA, Sarris AH, Cortes J, et al.: Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer 2006, 106:120–127.PubMedCrossRefGoogle Scholar
  41. 41.
    O’Brien S, Damon LE, Larson ML, et al.: Early signs of tolerability and activity in a phase 2 study of weekly vincristine sulfate liposomal injection (VSLI, Marqibo) in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) in second relapse or progressing following two anti-leukemia treatment lines [abstract 3959]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 3959.Google Scholar
  42. 42.
    Thomas DA, Kantarjian HM, Stock W, et al.: Phase 1 study of weekly vincristine sulfate (VCR) liposomes injection (VSLI, Marqibo™) plus dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia (ALL) [abstract 2930]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 2930.Google Scholar
  43. 43.
    Goekbuget N, Baumann A, Beck J, et al.: PEG-asparaginase in adult acute lymphoblastic leukemia (ALL): efficacy and feasibility analysis with increasing dose levels [abstract 302]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 302.Google Scholar
  44. 44.
    Douer D, Yampolsky H, Cohen LJ, et al.: Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood 2007, 109:2744–2750.PubMedGoogle Scholar
  45. 45.
    Hoelzer D, Thiel E, Loffler H, et al.: Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988, 71:123–131.PubMedGoogle Scholar
  46. 46.
    Faderl S, Thomas DA, Garcia-Manero G, et al.: Augmented hyper-CVAD in acute lymphoblastic leukemia(ALL): the MDACC experience with intensified L-asparaginase and vincristine in adult ALL salvage [abstract 1840]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 1840.Google Scholar
  47. 47.
    Faderl S, Thomas DA, Ravandi F, et al.: Intensification of hyper-CVAD with L-asparaginase, vincristine, and dexamethasone (“Augmented hyper-CVAD”) has activity in adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) [abstract 4324]. Blood (ASH Annual Meeting Abstracts) 2007, 110:Abstract 4324.Google Scholar
  48. 48.
    Esterhay RJ, Wiernik PH, Grove WR, et al.: Moderate dose methotrexate, vincristine, asparaginase, and dexamethasone for treatment of adult acute lymphocytic leukemia. Blood 1982, 59:334–345.PubMedGoogle Scholar
  49. 49.
    Jabbour E, O’Brien S, Thomas DA, et al.: Combination of the hyperCVAD regimen with dasatinib is effective in patients with relapsed Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL) and lymphoid blast phase chronic myeloid leukemia (CML-LB) [abstract 2919]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 2919.Google Scholar
  50. 50.
    Goldstone AH, Richards SM, Lazarus HM, et al.: In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG 2993). Blood 2008, 111:1827–1833.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  • Amber Fullmer
  • Susan O’Brien
  • Hagop Kantarjian
  • Elias Jabbour
    • 1
  1. 1.Department of LeukemiaThe University of Texas, MD Anderson Cancer CenterHoustonUSA

Personalised recommendations